Theriva biologics announces orphan drug designation granted by the u.s. fda for vcn-01 for the treatment of pancreatic cancer

Rockville, md., june 27, 2023 (globe newswire) -- theriva biologics (nyse american: tovx), (“theriva” or the “company”), a clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced that the u.s. food and drug administration (fda) has granted orphan drug designation to lead clinical candidate vcn-01, theriva's systemic, selective, stroma-degrading oncolytic adenovirus for the treatment of pancreatic cancer. in virage, the ongoing multinational phase 2b clinical study, intravenous vcn-01 is being evaluated in combination with standard-of-care (soc) chemotherapy (gemcitabine/nab-paclitaxel) as a first line therapy for patients with pancreatic ductal adenocarcinoma (pdac). previously, the fda granted orphan drug designation to vcn-01 for treatment of retinoblastoma.
TOVX Ratings Summary
TOVX Quant Ranking